Search 

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders

Illumina is a provider of Next Generation Sequencing technology

ImmunoBiochem is an immuno-oncology biopharmaceutical company that has developed a disruptive approach to targeting unique proteins amplified in cancer secretomes. These targets are secreted from cancer cells and accumulate in tumors, but not in normal tissues, and are constantly recycled in the tumor microenvironment. This novel approach enables the selective and efficacious delivery of immunomodulatory and chemotherapeutic payloads into relevant subsets of cells within the tumor microenvironment, including tumor cells, immune cells and tumor-supporting stroma.
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.

CRO Preclinical
In vivo efficacy evaluation in oncology

Pharmaceutical

Biologics Therapeutic development focUnited Statesed on oncology and IO. Looking for potential partnership opportunities for license in/out. www. KlUnited Statespharma.com

focus on early-stage life science investment

license-in paradigm shifting durgs to China patients

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs